Amgen Gets Into Position For MariTide Development
In an interview, CFO Peter Griffith pointed to a boost in capex to build out capacity for the obesity drug, which the company expects to move into Phase III development in the near term.
In an interview, CFO Peter Griffith pointed to a boost in capex to build out capacity for the obesity drug, which the company expects to move into Phase III development in the near term.